Biotech Analysts, along with Key Opinion Leader Dr. Gulamhusein of the TorontoCenter for Liver Disease and University Health Networ, discuss management of Primarily Biliary Cholangitis (PBC), along with the up-to-date development landscape, including ursodeoxycholic acid, obeticholic acid, elafibranor, and, relevant to CymaBay, seladelpar on an Analyst/Industry conference call to be held on August 8 at 11 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- 3 Best Stocks to Buy Now, 8/1/2023, According to Top Analysts
- CymaBay price target raised to $19 from $12 at H.C. Wainwright
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- CymaBay price target raised to $18 from $15 at BTIG
- Biotech Alert: Searches spiking for these stocks today